Modeling and Simulation of Orlistat to Predict Weight Loss and Weight Maintenance in Obesity Patients
作者： Kiyohiko Nakai , Russell Wada , Satofumi Iida , Takehiko Kawanishi , Yoshiaki Matsumoto
DOI: 10.2133/DMPK.DMPK-13-RG-100
关键词:
摘要: Summary: Orlistat is used clinically worldwide as anti-obesity drug. It a chemically synthesized hydrogenated derivative of lipstatin and an inhibitor gastric pancreatic lipases. has been found to reduce the absorption dietary fat in gastrointestinal tract. Modeling simulation based on pharmacokinetic/pharmacodynamic analysis becoming increasingly design clinical trials assure that are high quality conducted efficiently. We developed trial model for orlistat Phase III study data. This innovative weight loss includes relationships between dose, changes fecal excretion, loss, also incorporates dropout function. The guided dose-finding strategy allowed long-term outcomes orlistat.
elsevier.com
sci-hub.se 参考文章(12)
Peter L. Bonate, Clinical trial simulation in drug development Pharmaceutical Research. ,vol. 17, pp. 252- 256 ,(2000) , 10.1023/A:1007548719885
V A Bhattaram, C Bonapace, D M Chilukuri, J Z Duan, C Garnett, J V S Gobburu, S H Jang, L Kenna, L J Lesko, R Madabushi, Y Men, J R Powell, W Qiu, R P Ramchandani, C W Tornoe, Y Wang, J J Zheng, Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. Clinical Pharmacology & Therapeutics. ,vol. 81, pp. 213- 221 ,(2007) , 10.1038/SJ.CLPT.6100051
Kevin D Hall, Peter N Jordan, Modeling weight-loss maintenance to help prevent body weight regain The American Journal of Clinical Nutrition. ,vol. 88, pp. 1495- 1503 ,(2008) , 10.3945/AJCN.2008.26333
Stephan Rössner, Lars Sjöström, Rudolf Noack, A. Edo Meinders, Giorgio Noseda, , Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity Obesity Research. ,vol. 8, pp. 49- 61 ,(2000) , 10.1038/OBY.2000.8
Richard L. Atkinson, Treatment of obesity. Nutrition Reviews. ,vol. 50, pp. 338- 339 ,(2009) , 10.1111/J.1753-4887.1992.TB07722.X
M. Di Marco, J.F. Marier, M.P. Ducharme, I. Morin, C. Engel, S. Gulbranson, N.R. Thudi, D. Murpani, A. Rampal, T. Monif, T.S. Koundinya, K. Deo, T. Monif, Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions. principles and practice of constraint programming. ,vol. 46, pp. 319- 326 ,(2008) , 10.5414/CPP46319
Yaning Wang, A. Venkatesh Bhattaram, Pravin R. Jadhav, Lawrence J. Lesko, Rajanikanth Madabushi, J. Robert Powell, Wei Qiu, He Sun, Dong S. Yim, Jenny J. Zheng, Jogarao V. S. Gobburu, Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 The Journal of Clinical Pharmacology. ,vol. 48, pp. 146- 156 ,(2008) , 10.1177/0091270007311111
Michael H. Davidson, Jonathan Hauptman, Mario DiGirolamo, John P. Foreyt, Charles H. Halsted, David Heber, Douglas C. Heimburger, Charles P. Lucas, David C. Robbins, Jain Chung, Steven B. Heymsfield, Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat JAMA. ,vol. 281, pp. 235- 242 ,(1999) , 10.1001/JAMA.281.3.235
J Zhi, A T Melia, R Guerciolini, J Chung, J Kinberg, J B Hauptman, I H Patel, Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clinical Pharmacology & Therapeutics. ,vol. 56, pp. 82- 85 ,(1994) , 10.1038/CLPT.1994.104
B. D. Ripley, W. N. Venables, Modern Applied Statistics with S Fourth edition ,(2002)